[1] 郭文文,茆家定.结肠癌靶向治疗的研究进展[J].浙江临床医学, 2017, 19(5):973-975.
[2] 邱镜丹,李荣,王建东.Mina53基因与肿瘤的研究进展[J].现代肿瘤医学, 2015,23(11):1624-1627.
[3] 张立达, 白军伟, 白阳秋,等. H-cadherin在癌组织的表达及其临床意义[J].中华实验外科杂志, 2017, 34(2):291-293.
[4] 周小东,雷行华.原癌基因与造血系统恶性肿瘤的研究[J].实用医学杂志, 2017, 33(14):2407-2411.
[5] Ogasawara S, Komuta M, Nakashima O,et al.Accelerated expression of a Myc target gene Mina53 in aggressive hepatocellular carcinoma [J].Hepatol Res,2010, 40(4):330-336.
[6] 曹伟, 朱志坚, 李元平,等. Mina53蛋白在结肠腺瘤及结肠癌组织的表达及其临床意义[J].中华实验外科杂志, 2017, 34(2):294-296.
[7] 田永, 邹艳芳, 徐峰.大肠癌组织中Mina53和Mel-18蛋白的表达[J].郑州大学学报(医学版), 2013,48(6):780-783.
[8] Komiya K, Sueoka-Aragane N, Sato A,et al.Expression of Mina53, a novel c-Myc target gene, is a favorable prognostic marker in early stage lung cancer [J].Lung Cancer,2010, 69(2):232-238.
[9] 冯宁, 刘文志, 柳仲林,等. 胃癌中H-cadherin1甲基化与肿瘤生物学特性的关系[J].中华实验外科杂志, 2013, 30(7):1534-1534.
[10] Yan S, Wang H, Liu D,et al.Methylation of tumor suppressor gene CDH13 and SHP1 promoters and their epigenetic regulation by the UHRF1/PRMT5 complex in endometrial carcinoma[J].Gynecol Oncol,2016, 140(1):145-151. |
2018, Vol. 35 
